Health Condition 1: null- Patients with Major Depressive Disorder without any Axis I co-morbidity will be studied
Conditions
Interventions
Intervention1: YOGA THERAPY: Yoga therapy group will be given yoga training daily for 12 sessions by a trained yoga instructor and booster sessions, up to 12 weeks
Control Intervention1: CONVENTIONAL
Sponsors
Department of Science and Technology Govt of IndiaScience And Technology of Yoga And Meditation
Eligibility
Inclusion criteria
Inclusion criteria: Patients: 1.Subjects with DSM IV-TR clinical diagnosis of Major depressive disorder. 2.Severity of depression- moderate to severe and confirmed by a HAMD score >= 18 and absence of hypo/manic symptoms, defined as a YMRS score 3.Age 18 â?? 60 years 4.Both sexes 5.Patients who will consent for and be co-operative for yoga therapy. Healthy subjects: 1.Age from 18 â?? 60 years 2.Both sexes
Exclusion criteria
Exclusion criteria: Patients: 1.Co-morbid substance abuse (excluding nicotine dependence), psychosis, suicidal and self-injurious behavior, mental retardation, any other DSM IV-TR anxiety disorders, OCD and related disorders. 2.Severe depression with catatonic symptoms, suicidal risk or severe psychomotor retardation. 3.Bipolar depression. 4.Subjects with severe physical ailments like general medical conditions like coronary artery disease, fracture, active seizure disorders, auto-immune disorders, recent infection/inflammation as determined by ESR and CRP levels. 5.Subjects having pacemaker or metallic implants. 6.Pregnant, lactating or post-partum women. 7.Ongoing current practice of yoga or any other mind-body techniques (e.g., meditation, Tai-Chi, or related practices) of more than 45 minutes per week on average within the last 6 months or total estimated cumulative prior lifetime practice of more than 100 hours. 8.Those refusing consent. Healthy subjects: 1.Subjects with any psychiatric disorder as per DSM IV-TR (excluding nicotine dependence). 2.Subjects with severe physical ailments like general medical conditions like coronary artery disease, fracture, active seizure disorders, auto-immune disorders, recent infection/inflammation as determined by ESR and CRP levels. 3.Subjects having pacemaker or metallic implants. 4.Pregnant, lactating or post-partum women.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. A within-group (pre-post) comparison and between-group comparison of depression scores on Hamilton Depression Rating Scale (HDRS) at baseline and study completion.Timepoint: At baseline and 12 weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| A within-group comparison and between-group comparison of: 1.Depression scores on HDRS, MADRS, illness severity on CGI 2.Heart rate variability and of grades of cardiac autonomic dysfunction 3. Measures of cortical inhibition via TMS parameters 4.Change in EMALT (Emotion matching and labelling task) accuracy scores and differences in BOLD response on fMRI. 5.Plasma level of BDNF, IL-1β, and IL-6 Timepoint: At baseline, 4 weeks, 8 weeks, 12 weeks for depression severity as measured using rating scales. At baseline and 12 weeks for the other biological parameters | — |
Countries
India
Contacts
Public ContactMuralidharan K
National Institute of Mental Health And Neurosciences
Outcome results
None listed